NCT05064085
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with any previous treatment of a PD-1 or PD-L1 inhibitor, including cemiplimab; Patients with untreated unstable brain metastasis; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05064085